TY - JOUR
T1 - Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients
AU - Durand, Christine M.
AU - Marr, Kieren A.
AU - Arnold, Christina A.
AU - Tang, Lydia
AU - Durand, Daniel J.
AU - Avery, Robin K.
AU - Valsamakis, Alexandra
AU - Neofytos, Dionissios
N1 - Funding Information:
Financial support. The study was supported by the National Institutes of Health (grants K24, AI85118 and T-32, AI007291-21).
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Background. Cytomegalovirus (CMV) disease is the most common infectious complication after solid organ transplantation, frequently affecting the gastrointestinal (GI) tract. There are limited data on quantitative polymerase chain reaction (qPCR) for plasma CMV DNA as an adjunct diagnostic method for GI tract disease in kidney and liver transplant recipients. Methods. We reviewed all records of adult kidney and liver transplant recipients with a GI tract biopsy and plasma CMV qPCR result within 15 days of biopsy during a 6.5-year period at our center. CMV GI tract disease was defined as histopathologic evidence of CMV on biopsy by immunohistochemistry or visualization of inclusion bodies. Results. GI tract biopsy and qPCR results were available for 81 kidney and liver transplant recipients; 20 cases of confirmed CMV GI tract disease were identified. Overall, the sensitivity of qPCR for diagnosing CMV GI tract disease was 85% (95% confidence interval [CI], 61%-96%), and the specificity was 95% (95% CI, 85%-99%). For CMV-seronegative recipients (R-) with CMV-seropositive donors (D+), the sensitivity of qPCR was 100% (95% CI, 59%-99%), and the specificity was 80% (95% CI, 30%-99%). The lowest sensitivity was observed in CMV D+/R+ cases (72.7%; 95% CI, 39%-93%). The mean plasma CMV copy number in patients with GI tract disease was 3.84 log10 (38 334 copies/mL). Conclusions. Plasma CMV qPCR had good sensitivity and excellent specificity for CMV GI tract disease in kidney and liver transplant recipients. Its sensitivity was 100% in CMV D +/R- cases but 72.7% in CMV D+/R+ cases. This variation in assay performance according to host serostatus may reflect differences in disease pathogenesis.
AB - Background. Cytomegalovirus (CMV) disease is the most common infectious complication after solid organ transplantation, frequently affecting the gastrointestinal (GI) tract. There are limited data on quantitative polymerase chain reaction (qPCR) for plasma CMV DNA as an adjunct diagnostic method for GI tract disease in kidney and liver transplant recipients. Methods. We reviewed all records of adult kidney and liver transplant recipients with a GI tract biopsy and plasma CMV qPCR result within 15 days of biopsy during a 6.5-year period at our center. CMV GI tract disease was defined as histopathologic evidence of CMV on biopsy by immunohistochemistry or visualization of inclusion bodies. Results. GI tract biopsy and qPCR results were available for 81 kidney and liver transplant recipients; 20 cases of confirmed CMV GI tract disease were identified. Overall, the sensitivity of qPCR for diagnosing CMV GI tract disease was 85% (95% confidence interval [CI], 61%-96%), and the specificity was 95% (95% CI, 85%-99%). For CMV-seronegative recipients (R-) with CMV-seropositive donors (D+), the sensitivity of qPCR was 100% (95% CI, 59%-99%), and the specificity was 80% (95% CI, 30%-99%). The lowest sensitivity was observed in CMV D+/R+ cases (72.7%; 95% CI, 39%-93%). The mean plasma CMV copy number in patients with GI tract disease was 3.84 log10 (38 334 copies/mL). Conclusions. Plasma CMV qPCR had good sensitivity and excellent specificity for CMV GI tract disease in kidney and liver transplant recipients. Its sensitivity was 100% in CMV D +/R- cases but 72.7% in CMV D+/R+ cases. This variation in assay performance according to host serostatus may reflect differences in disease pathogenesis.
KW - CMV
KW - Colitis
KW - Kidney and liver transplant recipients
KW - Viremia
UR - http://www.scopus.com/inward/record.url?scp=84887859988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887859988&partnerID=8YFLogxK
U2 - 10.1093/cid/cit521
DO - 10.1093/cid/cit521
M3 - Article
C2 - 23956167
AN - SCOPUS:84887859988
SN - 1058-4838
VL - 57
SP - 1550
EP - 1559
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -